Adenosine Therapeutics

Partnering Opportunity

Partnering has always been key to the success of Adenosine Therapeutics, from its founding in 1999 to today. With the reacquisition of Stedivaze, Adenosine Therapeutics now possesses a unique partnering opportunity: a late Phase III drug program in a proven, growing market of more than $700M.

Clinical trial data to date suggest that Stedivaze® has the potential to demonstrate equivalent efficacy, compared to the standard of care, as well as best-in-class product attributes.

Two Phase III trials are 70% and 24% complete. Resumption and completion should be relatively straightforward and fast.

Stedivaze has a strong patent estate with a long life.

Adenosine Therapeutics is actively seeking a partner to help us bring this important and valuable drug to market. Interested parties are invited to contact us.

Invitees may visit our Virtual Data Room.

Home | Corporate | Partnering | Contacts
© 2013 Adenosine Therapeutics, LLC. All rights reserved.